Thermo Fisher Scientific (TMO) Holdings Trimmed by Burney Co.

Burney Co. cut its holdings in shares of Thermo Fisher Scientific (NYSE:TMO) by 11.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,407 shares of the medical research company’s stock after selling 315 shares during the period. Burney Co.’s holdings in Thermo Fisher Scientific were worth $497,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Schroder Investment Management Group lifted its stake in Thermo Fisher Scientific by 28.1% during the fourth quarter. Schroder Investment Management Group now owns 1,103,685 shares of the medical research company’s stock worth $209,568,000 after purchasing an additional 242,062 shares during the last quarter. Commerce Bank lifted its stake in Thermo Fisher Scientific by 1.6% during the fourth quarter. Commerce Bank now owns 227,763 shares of the medical research company’s stock worth $43,248,000 after purchasing an additional 3,577 shares during the last quarter. Swiss National Bank lifted its stake in Thermo Fisher Scientific by 2.2% during the fourth quarter. Swiss National Bank now owns 1,476,432 shares of the medical research company’s stock worth $280,345,000 after purchasing an additional 31,800 shares during the last quarter. Honeywell International Inc. lifted its stake in Thermo Fisher Scientific by 18.0% during the fourth quarter. Honeywell International Inc. now owns 230,000 shares of the medical research company’s stock worth $43,672,000 after purchasing an additional 35,100 shares during the last quarter. Finally, Lazard Asset Management LLC lifted its stake in Thermo Fisher Scientific by 14.3% during the fourth quarter. Lazard Asset Management LLC now owns 1,225,034 shares of the medical research company’s stock worth $232,608,000 after purchasing an additional 153,707 shares during the last quarter. Hedge funds and other institutional investors own 86.52% of the company’s stock.

Several equities research analysts have weighed in on the company. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $236.00 target price for the company in a research note on Thursday. Morgan Stanley upped their price target on shares of Thermo Fisher Scientific from $216.00 to $230.00 and gave the stock an “overweight” rating in a report on Thursday, April 26th. ValuEngine upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Friday, February 2nd. Finally, Bank of America upped their price target on shares of Thermo Fisher Scientific from $235.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, February 1st. One research analyst has rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $222.21.

In related news, Director William G. Parrett sold 1,000 shares of the stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $211.43, for a total value of $211,430.00. Following the completion of the sale, the director now directly owns 11,660 shares in the company, valued at $2,465,273.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 40,000 shares of the stock in a transaction on Thursday, March 22nd. The shares were sold at an average price of $210.16, for a total value of $8,406,400.00. Following the completion of the sale, the chief executive officer now owns 334,622 shares of the company’s stock, valued at $70,324,159.52. The disclosure for this sale can be found here. Insiders sold 43,500 shares of company stock valued at $9,129,330 over the last 90 days. 0.49% of the stock is currently owned by company insiders.

Shares of Thermo Fisher Scientific opened at $211.01 on Friday, Marketbeat.com reports. The firm has a market cap of $84.12 billion, a PE ratio of 22.23, a P/E/G ratio of 1.53 and a beta of 1.14. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 0.95. Thermo Fisher Scientific has a 52-week low of $209.10 and a 52-week high of $211.31.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, April 25th. The medical research company reported $2.50 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.42 by $0.08. The business had revenue of $5.85 billion during the quarter, compared to the consensus estimate of $5.62 billion. Thermo Fisher Scientific had a return on equity of 16.09% and a net margin of 10.24%. Thermo Fisher Scientific’s quarterly revenue was up 22.8% on a year-over-year basis. During the same period in the prior year, the business posted $2.08 earnings per share. sell-side analysts anticipate that Thermo Fisher Scientific will post 10.9 EPS for the current year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply